Next up is Nicole Paul. I'm really excited for this talk. I think you guys will find a lot of optimism in where technology is playing out in in biology and bioengineering to cure fundamental human disease. For nearly 20 years, she's been developing next-generation AAV platforms for gene repair, gene transfer, and gene editing. And she's directed evolution for novel engineered capsids and comparative multiomic approaches to interrogate translational AAV biology. She's gonna share a little bit about her work with her startup Siren Biotechnology, which came out of stealth last year. Please join me in welcoming Dr. Paulk to the stage.
We like your winter slide. All right quick show of hands, how many of you have ever even heard of the phrase gene therapy or viral gene therapy before? Oh my gosh, would you guys read Wall Street Journal in the Economist? Sorry, pretty good. Usually it's like two hands. So who the heck am I? And why am I in for talking to you about this? So like they said, my name is Dr. Nicole Paulk up until like a hot minute ago. I was a professor of viral gene therapy at UCSF in San Francisco and decided to spin out a company based off some work in my lab and I'm here to talk to you guys a little bit about using viruses as medicines.
So what is gene therapy? Broadly speaking, this is using viruses as medicines. So historically we have used these to treat single gene genetic disorders, but we can use these much more broadly now and I'll share a little bit about that. But historically we've used these when you were born either missing a gene in your genome or you had a mutation in a particular gene in your genome and all you needed in order to be completely healthy was to have a functional copy of that gene given back to you or to have the particular mutation in that gene corrected and restored for you and we can do all of these with viruses. And so if that sounds a little bit crazy and a little bit new and a little bit revolutionary, it's because it is. We're kind of quite literally living through one of the most recent and kind of newest eras of modern medicine.
And so in order to talk about where we are, we kind of need to understand where we came from. So nearly every one of you in this room, this first era of modern medicine started probably with your either your parents or your grandparents. This is with chemical medicines. This is when we realized that, gosh, every time I have a stomachache I can go eat this one particular leaf from a tree and when I eat that leaf I feel much better and then the scientists realized well we don't have to eat the leaf. We could isolate the chemical compound that comes from that leaf and then we could produce that in mass synthetically in large vats in the lab and that way we don't have to all go outside and eat and eat leaves all the time. And so the advent of chemical medicines and realizing that we could isolate these and synthesize these in mass was an absolute transformation. This is nearly every drug you've ever taken in your life. These are all the pills you can go find at your local pharmacy, particularly the ones that are over the counter. And so this is the vast majority of medicines you've ever taken in your entire life.
And the way these chemical medicines work, right? You take that pillow, you swallow it, it goes into your stomach, it gets dissolved by the acids in your stomach, it then gets absorbed into the bloodstream in your GI tract and then goes throughout your entire body and it will bind to and affect kind of either the shape or the function or the ability of various proteins in your body in a way that's useful to reduce your symptoms. And so then in the next kind of era of medicine we had the brilliant idea, well, let's just cut out the middleman. Let's not give you a chemical that alters the shape or function of a protein. Let's just give you the protein. Let's advance to protein medicines. And let's now take a protein that has the particular shape in the function that you might need in order to provide some kind of therapeutic benefit for the disease state that you have and give you that as a drug. And so that's kind of been the next kind of most recent wave of modern medicine. And so this is things like enzyme treatments and antibody therapies.
Many of you in the room have probably heard of the most successful drug of all time. Anyone know what it is? Anyone want to shout out a guess? What's the most successful drug of all time? That's raised the most money. It's not my agro, guys. Humira, someone said it. So this is an antibody that's used to treat a particular form of arthritis. This antibody sells on average a little over $21 billion worth of just that drug every single year and has been the most successful drug for the last 20 years. This is what we call a blockbuster. This is what everyone is shooting for in their portfolio as a blockbuster drug. And it's an antibody.
But now we're entering kind of this newest third modern form of medicine, which is what we call living medicines. This is using things like viruses, bacteria, cells, things that are quote unquote, alive that we can now use to go in and impart changes in your body.
Why would we do that? Well, both chemical medicines and protein medicines, we typically either give orally or we give intravenously, which means they're going to go throughout your entire body. But in some cases, we don't want a drug to go to your entire body. Like, for example, when you take chemo, boy, you feel like trash, right? It's because it's also affecting healthy cells in your body. So sometimes we want the medicine to only go into a simple place in your body or a single place. So that way you only experience the therapeutic effect in a single location.
The other really cool thing we can do with things like viruses and cells is we can engineer, I know many of you here, like tech or tech adjacent, we can engineer in logic circuits. So we can add things like if, then, or and, and all these types of kind of Boolean logic, we can engineer those circuits into viruses and cells and have them perform those same types of decisions within your body. Like, if you experience this, release the drug. If you experience this, don't. So you can engineer in these types of circuits in order to get this really, really precise delivery of any particular medicine that you're interested in delivering.
And you can package almost anything in a virus. And so a really common misconception is that all viruses are bad for you. All viruses make you sick. Couldn't be farther from the truth. The vast majority of viruses on the planet are very good at getting inside of you, but very few of them make you sick. I bet most of you can't name more than 20 viruses. And all the viruses you can name are viruses that make you sick, like measles, mumps, polio, smallpoxes, types of things. We only know of them because we studied them because they make us sick. But the vast majority of the viruses on the planet can actually kind of be considered our allies. They're tools that we can use that don't make us sick, but they're still very good at getting inside of us, that we can use to deliver all kinds of medicines.
So all of this is talk. Much more fun to look at is an actual video of this in action. And so what I'm going to show you on this screen is a patient from a clinical trial, from a patient that has a rare form of inherited genetic blindness. This is a disease called Lieber's Congenital Amorosis. These patients are born basically medically blind. They cannot see at birth.
And you're going to see two videos. The one on the left is going to be this patient pretreatment attempting to navigate a maze. You can see that maze on the floor at very, very low light. So the reason that this looks very yellow is because it's taken at one luminal unit or low light. All of us have much poorer visual acuity, a low light, then we do it highlight. So it's not that this video was taken in 1985. It was just in very, very low light. That's why it looks yellow.
So I'm actually going to start that video and I'll kind of talk over this patient while they're going. So this patient's medically blind. They cannot see the arrows on the ground that they're being told to navigate, nor can they see the little obstacles that they're being told like you should step over. So they're feeling for them with their feet, just like you would if you were blind and you didn't have your walking stick. You would just kind of feel in front of you to see what was there so that you wouldn't manage to trip and fall. So I'm not actually going to show you this entire video because it took this poor patient 214 seconds to attempt this navigate, this 8 foot, 8 foot by 8 foot maze. And all this patient needed, they were missing a single protein in the back of their eye. All they needed was a single viral infusion for that virus to express a single protein that that patient was missing in their eye.
And this is that exact same patient. Again, this was a 10 year old, just one year after treatment. They would have been able to do this within seven days though. So they have absolutely perfect vision. So we're able to keep the human blindness. This same young patient has now gone on to get their driver's license. They are walking, quite literally, they are walking amongst us, leading a completely normal life.
So this feels crazy and revolutionary like, oh my gosh, I hadn't heard about this. When is this coming for the rest of us in all of our indications? Soon. Where are we now? This is a one year old slide. The next prospectus from Wells Fargo is expected to come out any day now. I was hoping it would come out before this talk, but it didn't.
But this is the annual prospectus they put out every year. Kind of the advancement of these gene therapy companies, they do this for every industry, but this is for gene therapy. So this is all of the logos of all of the companies that are working in gene therapy for various diseases. The outer rings are kind of the earliest stages of development, those phase one, phase two trials. And as you move towards the center, towards the bullseye, that's when you're FDA approved and you can sell your drug for hopefully $21 billion a year and be a blockbuster.
But as you can see, right, there is a wave of gene therapies coming for even those few of you who didn't raise your hand earlier that you had ever heard of gene therapy before. I promise you, in your lifetime, no matter how old any of you are in this audience, in your lifetime, you are going to receive a viral gene therapy's medicine.
So there's a particular virus, Dave mentioned it earlier that I like to work on. This virus called AV. And it's typically used like we were mentioning before to treat rare genetic disorders. Some of the disorders that we've been able to cure are the ones shown here on this slide. And again, we've typically only done rare single gene disorders. And in my lab at UCSF and now at the company, we wanted to ask a little bit bolder question. Typically, we've only used these to treat rare genetic disorders. Could we use these to treat other indication spaces? Ones with many more patients where the need is much greater and the benefit to humanity would be much more.
So we wanted to ask a rather audacious question. Rather than having a virus that might cause cancer, could you use a virus to cure cancer? Could you actually use a virus as a medicine that could be used to treat cancer? So we've been working on this for the last seven years to try to go against conventional gene therapy.
So every gene therapy on the planet, all the ones on that bull's eye just showed you on the last slide, whether they're from academia, industry, big pharma, doesn't matter. Every one of those is bespoke and personalized for a single indication. So that virus that you make can only be used to treat that one disease and no other disease. And every one of those viruses takes about 10 to 15 years to develop. This is very time intensive. Usually on average, about two to three billion dollars. So maybe not necessarily as expensive as the gentleman who just left the stage, but a very, very expensive technology nonetheless. And typically treat very, very small patient populations. The definition of a rare disease in the United States is anything that occurs in fewer than 200,000 patients a year. But most of those gene therapies are going after indications with like 100 patients, 200 patients, so very, very rare disorders.
And so we wanted to go after something that would help much more of humanity. And so we wanted to ask the question, could we make a single gene therapy that could be used to treat millions of patients across a variety of indication spaces, things like cancer, where they're often very similar to one another? Could you make a universal gene therapy? Is that even a thing? And so we wanted to kind of set out on a fairly audacious project to not only bring viral gene therapy to the oncology world, but to blend it with one of the newest forms of oncology, which is this idea, this concept of immunotherapy. Many of you have maybe even heard of this before.
There's a variety of different ways you can accomplish this. They all essentially work the same way, where they retrain your immune system to fight cancer. And I'm using that word, retrain very purposefully. Every single one of you in this audience has a tumor. You've had a tumor every single day of your life. It's usually a single cell. You often have many of them throughout your body. Your immune system is doing what's called background cancer immunosurveillance. Your immune system is circulating throughout your body every single day, and it's actually able to detect and find and sniff out where those tumors are and get rid of them while they are, while they are still single cells.
How do they do this? It's a single tumor cell, wherever it is in your body. It sends out little chemical cues to the local environment as well as the immune system, and the healthy cells that surround that tumor are also able to detect something weird about that guy. And they'll send a little message over to the immune system and they'll be like, come over and do an investigation. Check him out.
What's up with him? Your immune system will come over, sniff it out and be like, yeah, I agree. Something's up with him. And they'll kill that cell. And this is happening all the time throughout your entire body. It's our immune system right now. Today. Your immune system knows how to fight cancer. It's exquisite at it. So how in the heck do you ever get a baseball-sized tumor? How does that happen? It happens because that individual tumor cell through a variety of different mechanisms, there are many ways this happens, but typically somehow, through one or two mechanisms, it will end up basically randomly generating a mutation that will give it essentially an invisibility cloak. That invisibility cloak makes it so that those neighboring healthy cells can't detect that something's up with it, so they don't send a message to the immune system. And because it's a little bit invisible, your immune system also can't just randomly swim by and detect it and see that something's wrong. And so because it can't be seen, it can't be destroyed, and so then it starts to grow and become your big baseball-sized mass, and then you become symptomatic, right? And then you go to the doctor.
But you can retrain your immune system to be able to see that invisible tumor, and if you can do that with immunotherapy, then now you've got a way to destroy a tumor that doesn't involve chemo, that doesn't involve radiation, that basically uses your own immune system to fight cancers. And so we wanted to blend the power of virology and therapy and the precision delivery and kind of those logic circuits around like, do this when you experience this, these types of things with immunotherapy to see if we couldn't do something important in the cancer space.
And so we developed a platform, a variety of different universal gene therapies in my lab at UCSF and spun those out into the company, and the name of the company is actually based off the mechanism of action here. So we can take these viruses, have them deliver a variety of different kind of cancer announcing payloads that will announce to immune system. The cancer is here, and so that way both the cancer cells, as well as the neighboring cells, will basically set off the fire alarm, pull the siren, and let the immune system know this is where we're going to be able to see that. So we're going to be able to see that the immune system know this is where the tumor is coming and fight it, and you'll have these three different waves of tumor killing that can happen both with your innate and your adaptive immune system.
So while we were still at UCSF, we were like, okay, we have this really cool idea, we want to try this, but we're agnostic to any particular cancer type because again, we weren't an oncology lab, we were a viral gene therapy lab. So we went over to our colleagues at the cancer center and we're like, what's the gnarliest cancer? What's the one that nothing works? And then they said, go after brain cancer. So we decided we'd start collaborating with folks at UCSF to determine a brain cancer kind of path. But how do you test a drug in order to make sure it works on human brain cancer when you can't test it yet on humans because the FDA wants you to have a data package before you go up for your clinical trial. So the way you test it is you actually make mice with human brain cancer.
So you can take brain cancer samples from humans, from biopsies and resections, transplant those into mice, they'll grow a mini human brain tumor, you can come in and now treat them with your human drug, not your mouse drug, your human drug to test if it works, and look to see whether or not you get a response. And this is a quick little sample from three mice from a treatment group where you can see those big colored blobs of the tumors in the brains of these mice. This is live, non-invasive, bioluminescent imaging, where the control treated mice that receive either a control virus, or just receive sterile saline, have massive tumors in mice dive versus the mice that have been treated with our virus, where we can completely eliminate these tumors. As you would imagine, if you can eliminate the tumors with imaging, that might just correspond to improvements in life expectancy.
This is the one and only graph that I'm showing you. Very simple. It's a survival curve. The line is vertical. You died. The line is horizontal. You lived. So we can massively improve the lifespans of these animals and for all intents and purposes, cure these mice of brain cancer. And we're queuing up for a clinical trial in 2025. So we're excited to start our clinical trial in 2025.
And very quickly, I'm going to share with you guys maybe like 15, three little 15-second vignettes on what else could we do with viruses? So we see a gentleman here sleeping. How many of you are short on sleep? Every one of you raise your hands. Come on.
So there is a rare mutation that happens in patients. These are people walking amongst us. We have a mutation in a gene called DEC2. These patients, again, single mutation, single gene. These patients only need four hours of sleep a night to be completely rested the same way that we have the need for eight to nine hours of sleep a night. You interested in getting this gene therapy? We could do this today. We haven't yet, but we could do this today.
Another example, most of us in the room, pretty probably interested in longevity. We could use viruses to regenerate the tissue in all of your joints, maybe get rid of things like cellulite, viruses, brain fog, all these types of things. This is probably a few more years out. We're probably five to ten years out on being ready to do this, but this is absolutely coming in your lifetime. You could get a rejuvenation gene therapy. You really want to talk far out? We could talk about maybe 30 years from now. We could absolutely engineer humanity to withstand life in much more drastically harsh environments. So we could alter your skin color to be able to reflect more UV light so you wouldn't get as much damage if perhaps say you were living on Mars. We could engineer the cells in your gut and bacteria that live in your gut to be able to metabolize foods that are more easily grown on a Martian environment and these types of things. So really, your imagination is the limit, so could we enhance human potential? We absolutely can. It's just a matter of are you interested in when? So happy to discuss the future. These are exciting times.
Can you just help everyone understand the timing and the regulatory hurdles? Viral gene therapy had a moment where there were setbacks and just share that with everyone, how this technology has been held back, how it's progressing now, and what timelines generally look like and how it's going to bring these breakthroughs to market.
Absolutely. So today, you were to start a brand new gene therapy company called SIRN Biotechnology or anything else. You wanted to develop a viral gene therapy and you wanted to get to clinic. You're still probably looking for that first program in a 10-15 year mark. It's not because it's going to take you that long to run the clinical trials. It's not going to take you that long to grow up the vats of the drug. It's mostly going to be a regulatory timeline.
So in between each one of these clinical trials, even before you do your very first ones, we're ready today. We could start our brain cancer clinical trial today, but we're looking at 18 months of paperwork in order to file to do that first phase one, and then you need to do your data readouts. In between each one of those trials, there's this kind of massive amount of paperwork that goes in front of the FDA that needs to be reviewed, and there's back and forths.
So the regulatory hurdles, both from if you weren't even doing anything really drastic like those last three vignettes that I talked about, is still going to be 10-15 years. But if you wanted to propose something like the sleep one that I mentioned that I think we'd all, I'm certainly interested in, there you're probably looking at an ethical review board and whether or not they let you do something like that, because that's not a disease. So fun fact, the FDA only lets you queue up clinical trials to test drugs that are for diseases. But aging is not a disease state. Wanting to sleep fewer hours is not a disease state. Insomnia is. But wanting to just sleep fewer hours and be fully rested is not a disease state.
So we kind of have to get to this moment where does the FDA start changing their definition of disease? Do we have a new regulatory body who will review these types of things that are more like augmentations and enhancements? How are we going to grapple with this as a society? Are we okay with this?
And let me just ask one more question. It's a great question you posed because there is increasing consensus that maybe we should think about aging itself as a disease, obviously, and that there's a lot of approaches now to addressing that.
What about the other challenges to completing the research and the trials and scalability? What are the bottlenecks? I've talked on our show about CAR-T therapy and the challenge in getting manufacturing scaled up to treat enough patients each year. Even though the technology is here, it's FDA approved, those drugs are in market, we just can't make enough. And I've heard a lot about lentivirus production and all these other kind of viral vectors being 18-month delay, super bottleneck.
How bottleneck are we in being able to do the research that you guys are doing and ultimately to get these products to market and make enough of the stuff to treat patients?
So the single biggest bottleneck is actually not technological at all. It's financial. It's access to capital. So these are, like I said, very, very capital intensive. The average viral gene therapy is about two to three billion dollars. So it's about three times more than making one of those chemical medicines. Some of that has to do with time, how long that process takes. Every year your company is operating. That GNA, ooh, expensive. It adds up really fast. And so some of this is just access to capital. And there's any company, every one of us in this room has a company. There's, depending on your sector, there's a valley of death.
For some of you, it's a very, very early stage. For some of you, it's a little bit more later stage, but there's a valley of death where you just can't access capital before you hit this big de-risking milestone where the bigger checks will come in and private equity and those types of groups and crossover funds in your IPO. So there's a valley of death for many of these early stage companies where, usually either after your seed stage or your series A, but before you've got clinical trial readouts where people are very nervous to give you a really big check. So that's certainly the biggest hurdle right now and why you see many companies going under across the biotech space regardless of if they're cell and gene therapies.
And then from the technological side, it's still manufacturing is just like the drumbeat. Being able to manufacture these things at scale continues to be a challenge. We need folks who come from the mechanical engineering in these types of backgrounds who don't historically necessarily think of biotech as a place where they could apply their knowledge and technologies to please come over to biotech and help us make new generations of bio reactors and types of things that will allow us to produce these at scale cleanly, cheaply, and easily. And it's just not intuitive. Making chemicals at scale is something that we've been doing for 40 years. So we're really good at it. Genentech can make kilos of drugs in an afternoon with a robot, but viruses are still something like if I queue up the biggest CDMO in the world, Cadillac pharma, and ask them to make us a 5,000 liter bioreactor of virus they'll absolutely say yes, but they won't even touch it for two and a half years.
I wanted to double click on the concept of making life better for people who aren't sick. The Marty Seligman from the American Psychological Association actually posed this question 20 years ago and he said what we try to make, all of psychology and psychiatry is taking depressed people and anxious people and making them less depressed and anxious. What about meaning and fulfillment for people who are content? What about more joy? And so when you look at the field and it's amazing the progress you're making and thank you for doing all that work, aside from hey can we sleep less? What else is, do you talk about, wow, if we had the mandate to take healthy people and give them a gift of augmenting them, making them into superheroes almost? We're talking about X-Men mutations here. What are the fun things that you dream about that you could do for humanity? Could we all just have vision like hawks or? Oh night vision is totally possible. Night vision? Yeah, easy. Literally without the goggles. Yeah, easy. I mean a world in which we. That's just an FDA like I need the green light, but no that's easy. So okay, that feels like Professor X kind of like shit, I like it. What else you got? Keep going.
我想进一步探讨如何为身体健康的人们改善生活的概念。美国心理学协会的马蒂·塞利格曼实际上在20年前提出了这个问题,他说我们试图做的是让心理学和精神病学能够让抑郁和焦虑的人变得不那么抑郁和焦虑。那么对于那些心满意足的人来说,有关意义和满足感的问题呢?还有更多的快乐?所以当你看着这个领域的进步,实现了那么多,感谢你所做的一切工作,除了减少睡眠时间以外,你还谈论了什么,哇,如果我们有责任将健康的人打造成超级英雄,给予他们增强自身能力的礼物呢?我们在谈论X战警中的变异能力。你对能为人类做的有趣事情有什么梦想?我们能都像鹰一样拥有敏锐的视力吗?哦,夜视完全可能。夜视?是的,很容易。甚至不用佩戴护目镜。是的,很容易。我是说,一个世界,在那个世界里...这仅仅是需要 FDA 批准的问题,但这很容易。所以好吧,感觉有点像X教授那样,很喜欢。你还有什么其他的想法?继续说吧。
Night vision would be possible the ability to metabolize a food that grows perhaps in a different environment that not only you can't get any nutrients from, but you can't even absorb it so we could make it so that you could pretend soil and it tasted good. You could eat anything and not only could it taste good to you, but it could provide you all the nutrients that you need and be able to grow with much less, much less water and in the types of environments that we'll have in the future planet given the climate change challenges that we all have.
As far as other augmentations, I mean there's all of the obvious beauty applications that I think all of us are already doing. Now we just be doing this with a different modality, right? There's a gene therapy company in San Diego working on male pattern baldness. There are folks working on all the wrinkles and cellulite and getting your hair color back and all of the normal beauty things that you would expect. That's absolutely coming, but as far as beyond the obvious beauty things like what other types of augmentations I think the mental health space is a huge one because it's usually a very, very simple thing. It's complex, but it's simple. They're usually missing a single receptor or a single protein somewhere in their brain and if we were just able to restore that for them in just that location and not everywhere in their body, you could restore joy. You could restore happiness, all of these types of things.
Do you want to talk about the capital markets piece because you mentioned you need capital? Yeah, we're fundraising. Hi. Yeah. And, uh, Tamar, maybe you can help out here, but, you know, the biotech market's been decimated since November of 21 and it's really intricately linked to interest rates because of how far out you have to make a bet on a biotech company and so as a result evaluations have plummeted 80, 90 percent. In many cases, a lot of stuff's just not getting funded right now. Um, maybe Tamar, you can share your point of view on where things are headed there and, um, Nicole, maybe you can share a little bit about what the experience has been fundraising even though you have a great technology that's got some proof points. How hard is it?
Well, I have a kind of a technical question, but which is just. You had to. when you picked AAV, you had to make a decision about small edits and not large edits, I guess, right? So just explain to these guys about what payloads are actually possible in AAV, and are you thinking about what happens if you actually have to go beyond 4KB and how are you going to solve that? So, sorry. Because a lot of the diseases that these guys will actually probably understand are not small snips. They're going to be large, you know, cut and paste.
Two types of gene therapy. There's gene transfer gene therapy, where we give you the whole gene that you were missing, like perhaps you were missing that portion of your chromosomal birth, so that's gene transfer gene therapy. We're literally transferring a functional copy of the gene back to you.
And then there's gene editing gene therapy where we go in and actually correct a mutation in place, uh, within your genome and don't give you anything extra.
然后,还有基因编辑和基因治疗,我们会进入体内实际上纠正基因突变的地方,不会给你添加任何额外物质。
So every virus on the planet has a carrying capacity. It has a size, just like a sedan, can't carry as much as a minivan. Um, and so AAV viruses, the viruses that I work on, are amongst one of the smaller viruses. So it can only package about 4.75KB. So the numbers of nucleotides that you can fit inside of it, and different viruses have larger packaging capacities and can fit more stuff, more packages inside. That's 4,700 letters of DNA. Um, and so different viruses will have different packaging capacities.
And so if you're doing gene transfer gene therapy where you need to provide the entire copy of the gene, you can only put in genes that will fit with all of the other regulatory elements for expression within that virus. So of all protein coding genes, since we're typically going after diseases that are influencing a protein, of all protein coding genes, 80% of those genes can fit within my virus. So actually the vast majority of genetic diseases can be treated with AAV gene therapy, with gene transfer gene therapy.
With gene editing gene therapy, we can treat anything because now we're not size limited. We only need to deliver either the nicker or the cutter, right? Many of you have heard of things like CRISPR. That's one of the many tools we can use to nick or cut DNA. And we can either make a nick and have your body repair the mutation. We can go in and make a nick or a cut, and we can cut something out that wasn't supposed to be there. Or we can go in and nick or cut something in your genome, cut something out, and then put something that was meant to be there the whole time back in. All three of those forms, those gene repairs and gene edits are all kind of broadly classified as gene editing gene therapy. And all of those would fit within any virus.
There's a high percentage of disease, I don't know the percentage you probably know, which is really just like one point mutation, right? Yeah. Huge transcribe AC or something is typically the biggest one, right? Can you just explain to folks, when you think the tool chain will exist for us to do those single point edits and actually just. Today. You can actually go in and accurately rewrite an A to a C. Today. Yeah, there's a few in. Yeah, there's some.
So, um, guys, we gotta wrap and I want to really thank Dr. Nicole Paulk for her amazing work and for joining us. Thank you. Thank you. Okay. Fantastic.
Thank you so much. Thank you. Thank you. You got a nice standing here. Thank you. Thank you.
非常感谢你。谢谢你。谢谢你。你在这里的位置很好。谢谢你。谢谢你。
You've got a nice standing here. What are you doing? I'm doing your winter slide. Rain man, David Saffs. I'm doing it all. And it said we open sources. And they've just gone crazy with rain. Romulus. Nice. We know we know we're gonna survive.